Related Experiment Video
Updated: Apr 22, 2026
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds
Published on: April 6, 2016
Bioengineered In Vitro 3D Cancer Models: A New Paradigm in Ethical and Predictive Oncology Research Toward Successful
Chitra Jaiswal1, Bibrita Bhar1, Saki Sugihara1
1Biomaterials and Tissue Engineering Laboratory, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, Assam, India.
Abstract:
The pharmaceutical industry is confronting a significant challenge due to the high rate of drug attrition, largely because of reliance on 2D cell culture and animal models for pre-clinical validation. From this perspective, in vitro 3D cancer models offer a transformative tumor mimicry platform by enabling tunable and precise control over spatial organization and microenvironmental cues. Emerging advanced technologies such as 3D bioprinting, microfluidics, and multi-organ-on-a-chip systems have further enhanced the utility of these models for toxicity screening and accurate drug response prediction. This review comprehensively explores the various aspects of heterogeneity inherent within TME and their pivotal role in tumor progression, and determines the therapeutic outcomes. Special emphasis is placed on discussing diverse bioengineering techniques, evaluating their respective advantages and limitations, and the importance of integrative approaches to overcome the existing challenges. By recapitulating multifaceted aspects of the TME through hybrid bioengineering techniques, these platforms hold immense promise to improve predictive accuracy of pre-clinical anticancer drug screening and accelerate the timeline for novel drug development. Overall, the adoption of bioengineered in vitro 3D cancer models offers a humane alternative with enhanced reproducibility and scalability compared to traditional models, thereby advancing ethical oncology research in alignment with the 3Rs principle.
Insights
Three-dimensional (3D) in vitro cancer models offer improved pre-clinical drug screening by mimicking tumor microenvironments (TME). These advanced bioengineered models enhance drug response prediction and accelerate novel therapeutic development.
Area of Science:
- Oncology
- Bioengineering
- Drug Discovery
Background:
- High drug attrition rates in pharmaceuticals stem from limitations of traditional 2D cell cultures and animal models.
- In vitro 3D cancer models provide superior tumor mimicry through controlled spatial organization and microenvironmental cues.
- Advanced technologies like 3D bioprinting and microfluidics enhance these models for toxicity screening and drug response prediction.
Purpose of the Study:
- To review the role of tumor microenvironment (TME) heterogeneity in tumor progression and therapeutic outcomes.
- To explore diverse bioengineering techniques for creating advanced 3D cancer models.
- To evaluate the advantages, limitations, and integrative approaches for overcoming challenges in 3D cancer modeling.
Main Methods:
- Comprehensive review of existing literature on 3D cancer models and bioengineering techniques.
- Analysis of tumor microenvironment (TME) heterogeneity and its impact on cancer progression.
- Evaluation of advanced technologies including 3D bioprinting, microfluidics, and organ-on-a-chip systems.
Main Results:
- 3D cancer models effectively recapitulate TME complexity, improving predictive accuracy for pre-clinical drug screening.
- Bioengineered platforms enhance the understanding of tumor progression and therapeutic outcomes.
- Integrative approaches combining multiple bioengineering techniques offer robust solutions to current challenges.
Conclusions:
- Bioengineered 3D cancer models are transformative platforms for accurate pre-clinical drug validation and development.
- These models offer a more humane, reproducible, and scalable alternative to traditional methods, aligning with the 3Rs principle.
- Adoption of these advanced models promises to accelerate the development of novel anticancer therapies.
